|Targets||Neuropeptide Y receptor|
|Description||Antagonist G is a substance P analog, which is a broad spectrum neuropeptide growth factor antagonist and antiproliferative agent. It was developed for the treatment of small cell lung cancer. It could inhibit neuropeptide-dependent and -independent proliferation of small cell lung cancer in vitro. It also inhibits growth of SCLC xenografts in mice in vivo. It blocks Swiss 3T3 cell growth induced by vasopressin, gastrin-releasing peptide and bradykinin. It activates JNK and stimulates apoptosis. It is an anticancer agent and is resistant to degradation by peptidases.|
Pancreatic Polypeptide (human)
Pancreatic polypeptide is an agonist of neuropeptide Y (NPY) receptors that reduces forskolin-induced cAMP accumulation in L-M(TK-) cells recombinantly expressi...
Neuropeptide Y (human, rat)
Neuropeptide Y (human, rat) is a widely distributed endogenous neuropeptide involved in the control of food intake, sexual behavior and blood pressure. NPY has ...
PD 160170 is a potent, selective non-peptidic neuropeptide Y1 receptor antagonist (Ki = 48 nM), which is selective over Y2 and Y5 receptors (Ki > 10 μM).
CYM 9484 has been found to be an effective neuropeptide Y (NPY) Y2 receptor antagonist.
A Y5 receptor-selective agonist (IC50 values for inhibition of NPY binding to human Y5, Y1, Y2 and Y4 receptors are 0.24, 530, > 500, and 51 nM respectively, Ki...
Neuropeptide SF (mouse, rat)
Neuropeptide SF (mouse, rat) is a neuropeptide FF receptor agonist (Ki= 48.4 and 12.1 nM for NPFF1 and NPFF2, respectively). NPSF may play a physiologic role in...
Neuropeptide Y 13-36 (porcine)
Neuropeptide Y 13-36 (porcine) is a selective neuropeptide Y2 receptor agonist (Ki = 0.18 nM). It mimics the effects of NPY at presynaptic receptors in vas defe...
JNJ 5207787 has been found to be a selective NPY Y2 antagonist (IC50 = 0.1 μM).